Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Special Meeting of Shareholders for Aptose Biosciences (APS:CA) scheduled March 31, 2026 at 11:00 AM EDT, chaired by William Rice with CFO Fletcher Payne and CMO Rafael Bejar participating. The company is holding a virtual-only meeting via Lumi; votes will be conducted by poll with registered shareholders and proxies entitled to one vote per share. The excerpt contains procedural and logistical details only and discloses no material financial, operational, or strategic updates.

Analysis

A governance-focused shareholder event in a small-cap biotech often compresses the information premium into a short window; market moves tend to be driven less by fundamentals and more by vote outcomes, rumor, and option positioning. Expect 10–30% intraday moves around proxy results or announcements tied to board/compensation/financing resolutions — these are liquidity-driven, not clinical-signal driven, and therefore create predictable short-term volatility.

Second-order effects matter: a perceived need for near-term cash or an unclean governance vote can trigger payment reprioritization with CROs/CDMOs, slowing timelines for IND-enabling or trial activities and ceding enrollment momentum to peers. Competitors with ready cash or partnered programs can exploit any execution gap by accelerating readouts or filing for competing indications, compressing monopoly windows that underpin upside valuations.

Tail risks are concentrated and timebound: dilutive financing or an adverse board vote can halve market cap within weeks, while a credible non-dilutive strategic partnership or spate of board/management changes can re-rate shares 50–100% over 3–12 months. Key reversals come from announced capital structures (equity, convertible, warrants), partner term sheets, or definitive clinical/registry milestones; monitor filings and proxy statements on a daily cadence for keystone language that moves probability of those outcomes.

Key Decisions for Investors

• Event-driven long (APS.TO) — Size 1–2% NAV long below a 15% post-vote drop; target 30–60% upside over 6–12 months if the vote reduces short-term governance uncertainty or the company secures a non-dilutive partner. Hard stop at 30% loss; reason: buys idiosyncratic optionality at depressed sentiment with defined downside.
• Protective put spread (hedge) — Buy a 3-month put ~15% OTM and sell a further OTM put 35–45% OTM to finance ~50–70% of the cost, sized to protect 3–5% NAV. Rationale: asymmetric protection against a financing-driven tail while limiting premium paid given likely jump volatility.
• Pairs trade (idiosyncratic vs sector) — Long APS.TO / Short IBB or XBI sized dollar-neutral (rebalance weekly) over 3–9 months to isolate governance/firm-specific upside while neutralizing biotech sector beta. Exit if sector correlation breaks (>0.6 intraday) or if a definitive capital/partnering announcement occurs.
• Catalyst speculative long (small size) — Allocate 0.5% NAV to near-the-money calls (3–6 month) only if a proxy filing signals potential constructive board changes or an exclusive partnering process; asymmetric payoff if market re-rates governance and unlocks M&A interest. Limit to option premium loss as max downside.